The Canadian Cancer Trials Group CO.26 study assessed the effect of combined immune checkpoint inhibition with anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 and anti-PD-L1 blockade compared with that of the best supportive care alone in patients with advanced CRC [42]. Here, CTLA4 is linked to colorectal carcinoma.